D
iabetic patients have been previously reported as having an altered proteoglycan metabolism, which results in decreased content of heparan sulfate proteoglycans in basement membranes (1). Proteoglycans consist of a core protein to which glycosaminoglycan chains are attached. The biosynthesis of the glycosaminoglycan chains is initiated by a xylosylation of the proteoglycan core protein. Xylosyltransferase (XT)-I and -II (enzyme commission [EC] no. 2.4.2.26) catalyze the initial and rate-limiting step in glycosaminoglycan biosynthesis and have been shown to play an important role in proteoglycan homeostasis (rev. in 2). XT-I and XT-II are Golgi-resident proteins that are shed from the Golgi membrane and are secreted into the extracellular space attached to large proteoglycans. Consequently, XT activity present in blood has been proposed as a biochemical marker for the determination of an enhanced proteoglycan biosynthesis rate (2).
Hyperglycemia has been shown to affect a series of cellular processes including glycosylation (3,4). In diabetic patients, the biosynthesis of heparan sulfate proteoglycans has been found to be decreased (5,6), and a reduced heparan sulfate glycosaminoglycan content has been reported in the arteries of diabetic patients (7). Furthermore, the association between diabetes and heparan sulfate glycosaminoglycans and impaired organ function has been intensively studied in the kidneys, where heparan sulfate proteoglycans are important components of the glomerular basement membrane (8,9).
RESEARCH DESIGN AND METHODS -The study cohort comprised 100 unrelated Caucasian diabetic patients (50 male, aged 53 Ϯ 8 years; 50 female, aged 54 Ϯ 7 years) and 100 unrelated age-and sex-matched blood donors with normal blood glucose levels (3.9 -5.6 mmol/l). Within the patient cohort, 35 were type 1 diabetic (17 male, aged 26 Ϯ 12 years; 18 female, aged 29 Ϯ 11 years) and 65 patients were type 2 diabetic (33 male, aged 56 Ϯ 9 years; 32 female, aged 57 Ϯ 12 years). The definition of type 1 and type 2 diabetes was according to current American Diabetes Association and World Health Organization recommendations (10). Disease duration was at least 5 years in all patients. The experimental design was approved by the local ethics committee, and all patients gave informed consent. Blood was drawn after overnight fast, and determination of XT activity was performed as described previously (11). Statistical analysis was performed using the Student's t test and the Kolmogoroff-Smirnoff test where appropriate. Normality testing for Gaussian distribution of values was performed using the F test, and multiple linear regression analyses were used to assess the independent role of the serum XT activity as well as sex, age, A1C, duration of diabetes, and other serum parameters (alanine aminotransferase, aspartate aminotransferase, bilirubin, calcium, cholesterol, cholinesterase, C-reactive protein, creatine kinase, creatinine, ␥-glutamyl transferase, HDL cholesterol, lactate dehydrogenase, LDL cholesterol, potassium, sodium, total protein, triglycerides, urea, and uric acid). P values Ͻ0.05 were considered statistically significant.
RESULTS -XT activities in male diabetic patients (n ϭ 50) were significantly reduced in comparison with those in the control group (P Ͻ 0.0001). The mean Ϯ SD (90% range) was 19.3 Ϯ 4.44 mU/l (13.2-26.6) in male diabetic patients and 26.6 Ϯ 2.79 mU/l (18.1-29.1) in nondiabetic male control subjects (n ϭ 50, respectively) (Fig. 1) . XT activities in serum specimens from female diabetic patients were also significantly decreased compared with those from nondiabetic female control subjects (P Ͻ 0.0001). In female diabetic patients (n ϭ 50), the mean Ϯ SD (90% range) was 18.9 Ϯ 3.14 mU/l (14.6 -24.4) (Fig. 1) . In the corresponding group of female nondiabetic control subjects (n ϭ 50), the mean Ϯ SD XT activities (90% range) was calculated as 21.8 Ϯ 3.74 mU/l (15.3-29.2). The serum XT activities did not differ between patients with type 1 (19.9 Ϯ 3.60 mU/l) and type 2 diabetes (18.7 Ϯ 3.91 mU/l). The observed differences in serum XT activities remained significant after adjustment for sex, age, A1C, duration of diabetes, and other serum parameters as listed above. Furthermore, no significant correlation of the serum XT activities and these parameters was observed.
CONCLUSIONS -In the diabetic state, a reduced biosynthesis of proteoglycans has been described (5,6,12). A decrease in the glycosaminoglycan content has been reported for multiple tissues including arteries (7), glomerular basement membranes, or the endothelium (12). The associations between hyperglycemia, glycosaminoglycan concentration, and impaired organ function have been well studied in the kidneys (1). These alterations point to those enzymes involved in the biosynthesis of the glycosaminoglycan chains and to both their regulation and enzymatic activity as potential modifiers of this process.
XT-I and XT-II catalyze the initial and rate-limiting transfer of xylose to selected serine residues of the proteoglycan core protein (2). Both enzymes are shed from the Golgi membrane and are released into the extracellular space attached to large proteoglycans (2,13). Therefore, the XT activity in body fluids reflects the actual proteoglycan biosynthesis rate. While the biological role of XT secretion is not understood, the quantification of XT activity in the peripheral blood and other body fluids could be successfully validated as a marker of the actual proteoglycan biosynthesis rate (2).
In the present study, we show for the first time reduced XT activity in diabetes, a disease in which a reduced proteoglycan biosynthesis rate has been demonstrated (7, 8, 12) . This low XT activity is proposed to result from a decreased enzyme biosynthesis rate or a lowered release from the Golgi apparatus; however, an increase of enzyme turnover or an elimination of the enzyme from the blood stream must also be taken into account. Furthermore, there is a significant overlap in the XT activities of diabetic patients and normal subjects pointing to multiple factors affecting the individual serum XT activity. The XT activity determined in peripheral blood is supposed to be a mixture of XT-I and XT-II enzyme activity, as both enzymes are released into the extracellular space and share highly similar acceptor specificity. To date, neither immunologic nor enzyme activity assays that are suitable for discriminating between the two XT isoforms are available. The future development of XT-I -and XT-II-specific assays will help to elucidate whether diagnostic advancement is achieved by a selected determination of the XT isoforms.
